Efficacy and immune correlates of the SRA737 plus LDG regimen in combination with antiPDL1 in an SCLC model

Efficacy and immune correlates of the SRA737 plus LDG regimen in combination with anti-PD-L1 in an SCLC model

12:08 EDT 15 Apr 2019 | ecancermedicalscience

Dr Triparna Sen speaks to ecancer at the 2019 American Association for Cancer Research (AACR) meeting about results from a study looking at the efficacy and correlates of immunity of the combination treatment involving CHK1 inhibitor SRA737 plus low dose...

More From BioPortfolio on "Efficacy and immune correlates of the SRA737 plus LDG regimen in combination with anti-PD-L1 in an SCLC model"